Safeguarding
ORGANs.
Saving Lives.

 
080877908-laboratory-worker-examining-RET.jpg

ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS.

Our therapeutic programs modulate the natural protective, reparative and regenerative pathways of the body in both orphan diseases and larger clinical indications.

Our robust pre-clinical and clinical portfolio targets areas of high unmet medical need across a spectrum of therapeutic indications, including acute kidney injury (AKI) and chronic kidney disease (CKD).

 

ANGION’S MISSION is
to deliver effective therapies that heal injured organs and save lives.

 
80960768_l.jpg

LATEST NEWS

04/03/2019

Angion Awarded $4.76 Million Department of Defense Grant for Chronic Kidney Disease Drug Candidate ANG-3070

01/04/2019

Angion Completes Equity Financing and Appoints Senior Executives

11/27/2018

Angion Biomedica to present at Piper Jaffray Healthcare Conference

34536473_xl (1).jpg
 



patient Advocacy

Collaborating with patients AND THEIR FAMILIES in the fight against IRREVERSIBLE ORGAN DAMAGE

62599761_xl.jpg